Chenyu Lin
Duke University · Duke Health
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Chenyu Lin as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 16:38 UTC. Open this list on ClinicalTrials.gov
- N/ANCT06415656 · VitalTraq for the Detection of CRSDuke University · completed · Hematologic Malignancy · principal investigator
- Ph1NCT06233110 · Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHDStefanie Sarantopoulos, MD, PhD. · recruiting · Chronic Graft Versus Host Disease · principal investigator
- N/ANCT05520346 · Testing a Device for Automatically TRacking Urine and STool in an Inpatient HCT Setting (Project TRUST)Duke University · recruiting · Fluid Output · principal investigator
- N/ANCT05238376 · Survivorship Post-HCT Optimization ProgramDuke University · completed · Hematologic Malignancy · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 16:38 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 16:38 UTC. The ranking covers the 200 most relevant of 1610 PubMed records, and a shared surname and initials can bring in a namesake. All 1610 on PubMed
- 983 citationsRCR 35.4
- 802 citationsRCR 41.8
- Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Respir Med · 2020566 citationsRCR 30.9
- 309 citationsRCR 23.8
- Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study.J Clin Oncol · 2022291 citationsRCR 18.2
- Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol · 2021212 citationsRCR 11.8
- 178 citationsRCR 5.8
- 158 citationsRCR 15.1
- Tocilizumab Prevents Progression of Early Systemic Sclerosis-Associated Interstitial Lung Disease.Arthritis Rheumatol · 2021151 citationsRCR 10.7
- Opioid analgesia for acute low back pain and neck pain (the OPAL trial): a randomised placebo-controlled trial.Lancet · 2023128 citationsRCR 22.7